DNA RNA and Cells

03 Dec 2018 bluebird bio and Celgene Corporation Present Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
03 Dec 2018 Autolus Therapeutics Presents Initial AUTO3 Clinical Data from Phase 1/2 Clinical Trials in B cell Malignancies at the 60th ASH Annual Meeting
03 Dec 2018 Spark Therapeutics Announces Updated Data on SPK-8011 from Ongoing Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 60th American Society of Hematology (ASH) Annual Meeting and Exposition
03 Dec 2018 Editas Medicine Announces Pre-Clinical Data Supporting Novel Approach for Treatment of Sickle Cell Disease and Beta-Thalassemia
03 Dec 2018 Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 Study ATTCK-20-03 at the 2018 ASH Annual Meeting
03 Dec 2018 Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1
03 Dec 2018 A single infusion of FLT180a resulted in sustained mean Factor IX activity of 45%, with no toxicity or adverse effects, and eliminated need for patient infusions of FIX replacements
02 Dec 2018 Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018
02 Dec 2018 Stoke Therapeutics Presents Data Showing Single Dose of ASO Therapy Restores Normal Protein Levels in Animal Model of Genetic Epilepsy
02 Dec 2018 MaaT Pharma Presents Positive Phase 1b/2a Study Results in Acute Myeloid Leukemia Patients at the ASH 2018 Annual Meeting
02 Dec 2018 Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL)
02 Dec 2018 Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant
02 Dec 2018 Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 Study ATTCK-17-01 at the 2018 ASH Annual Meeting
02 Dec 2018 Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers
01 Dec 2018 Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101
01 Dec 2018 Turnstone Biologics Unveils Novel Vaccinia Oncolytic Viral Immunotherapy Platform
01 Dec 2018 Editas Medicine Announces FDA Acceptance of IND Application for EDIT-101
28 Nov 2018 Cold Genesys Announces Clinical Trial Collaboration to Evaluate the Combination of CG0070 and KEYTRUDA® (pembrolizumab) in Bladder Cancer
28 Nov 2018 Oncorus Announces Nomination of ONCR-177, A Next-Generation Oncolytic Virus Therapy Clinical Candidate for Multiple Solid Tumor Indications
28 Nov 2018 FDA Clears SpinalCyte IND Application for Universal Donor Cell Therapy to Treat Lower Back Pain
28 Nov 2018 Mustang Bio Announces Presentation of MB-102 (CD123 CAR) Safety and Efficacy Data at AACR Special Conference on Tumor Immunology and Immunotherapy
28 Nov 2018 Celgene Corporation and bluebird bio Complete Enrollment of Pivotal KarMMa Study of anti-BCMA Car T Cell Therapy bb2121 in Patients with Relapsed and Refractory Multiple Myeloma
28 Nov 2018 Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy
27 Nov 2018 Rocket Pharmaceuticals Announces Preclinical Data for AAV-Based RP-A501, the First Investigational Gene Therapy Program for a Monogenic Heart Failure Syndrome
27 Nov 2018 Vedanta Biosciences Announces Initiation of Phase 1 Clinical Study with Janssen of Microbiome-Derived Product Candidate for Inflammatory Bowel Disease

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up